SCLN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SCLN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-26), SciClone Pharmaceuticals's share price is $11.15. SciClone Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2017 was $0.68. Hence, SciClone Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is 16.52.
The historical rank and industry rank for SciClone Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:
SciClone Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Jun. 2017 was $0.28. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2017 was $0.68.
The historical data trend for SciClone Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SciClone Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | |||||||||||
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | 5.75 | 30.73 | 16.72 | 14.67 | 16.39 |
SciClone Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | |
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | 19.58 | 16.22 | 16.39 | 18.99 | 16.30 |
For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where SciClone Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.
SciClone Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
= | 11.15 | / | 0.675 | |
= | 16.52 |
SciClone Pharmaceuticals's Share Price of today is $11.15.
SciClone Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.68.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Price-to-Operating-Cash-Flow Ratio | = | Market Cap | / | Cash Flow from Operations |
Thank you for viewing the detailed overview of SciClone Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard J Hawkins | director | 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125 |
Nancy T Chang | director | 101 WESTCOTT, SUITE 603, HOUSTON TX 77007 |
Raymond Anthony Low | director, officer: VP, Finance & Controller | 25 SHADOW TREE CT, DANVILLE CA 94506 |
Wilson Wai-shun Cheung | officer: CFO & Senior VP, Finance | SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404 |
Jon S Saxe | director | FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Robert King | officer: SVP of Prod. Dev/Supply Chain | 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404 |
Winnie Wing-kei Tso | other: VP, Finance and Controller | 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404 |
Stephanie Wong | officer: VP, Finance and Controller | 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080 |
Gary Titus | officer: Senior VP Finance & CFO | SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125 |
Peter Barrett | director | C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142 |
Spa Essetifin | 10 percent owner | VIA SUDAFRICA 20, ROME L6 00144 |
Paolo Cavazza | 10 percent owner | VIA TESSERETE, 10, LUGANO V8 V8 |
Farmaceutica Lda Defiante | 10 percent owner | RUA DOS FERREIROS,260, FUNCHAL MADEIRA S1 9000-082 |
Dean S Woodman | director | 233 MOCKINGBIRD TRAIL, PALM BEACH FL 33480 |
From GuruFocus
By riddock57 riddock57 • 03-12-2015
By gurufocus • 08-07-2009
By gurufocus • 05-26-2009
By gurufocus 10qk • 12-06-2010
By gurufocus 10qk • 11-08-2010
By gurufocus • 05-26-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.